<DOC>
	<DOCNO>NCT01766063</DOCNO>
	<brief_summary>The study aim investigate relationship sleep quality , quality life , disorder therapy Multiple Sclerosis ( MS ) patient treat Betaferon .</brief_summary>
	<brief_title>Investigating Relationship Between Sleep , Quality Life , Other Disorders Therapies MS Patients Betaferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients ≥ 18 year age relapse remit multiple sclerosis clinically isolated syndrome expand disability status scale score ≤5 . Patients must treatment Betaferon tolerate Betaferon accord investigator 's evaluation , receive Betaferon longer six month . Written informed consent must obtain Patients tolerate Betaferon accord investigator 's evaluation treat Betaferon six month . Patients receive disease modify drug MS specific treatment Contraindications Betaferon describe Summary Product Characteristics .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Sleep</keyword>
	<keyword>Quality life</keyword>
	<keyword>Observational study</keyword>
</DOC>